Abstract【Objective】 To investigate the clinical efficacy of programmed death protein 1 (PD-1) monoclonal antibody combined with microwave ablation in the treatment of primary liver cancer. 【Methods】 The clinical data of 78 patients with primary liver cancer admitted to our hospital from January 2019 to October 2020 were analyzed retrospectively. According to the different treatment methods, they were divided into combined group (treated with PD-1 monoclonal antibody combined with microwave ablation) and control group (treated with single microwave ablation), with 39 patients in each group. The clinical efficacy, immune function and adverse reactions of the two groups were compared, and the survival rate was analyzed by Kaplan-Meier. 【Results】 The disease control rate and objective remission rate in the combined group were higher than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of CD39+ and CD73+ in both groups were lower than those before treatment, and those in the combined group were lower than those in the control group (P<0.05). The incidence of rash in the combined group was higher than that in the control group (P<0.05); There was no statistically significant difference in the occurrence of other adverse reactions between the two groups(P>0.05). The difference between the two groups was statistically significant (P<0.05). 【Conclusion】 PD-1 monoclonal antibody combined with microwave thermal ablation is helpful to improve the disease control rate and prolong the survival time of patients with primary liver cancer, and has certain safety.
HOU Long-hui,WEI Yang-chao. Clinical Efficacy of PD-1 Monoclonal Antibody Combined with Microwave Ablation in the Treatment of Primary Liver Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(1): 95-97.
[1] 孟庆萍,樊强.慢性乙型肝炎并发原发性肝癌的流行情况调查及影响因素[J].中国卫生工程学,2021,20(4):573-575. [2] 林川,王秋,游昕.射频消融与微波消融联合放疗对伴门静脉癌栓原发性肝癌患者的治疗效果比较[J].肝脏,2021,26(2):167-170. [3] THOMAS S,PRASANNA T A,DEVI P U,et al.Therapeutic drug monitoring of sorafenib in hepatocellular carcinoma patients[J].Ther Drug Monit,2020,42(2):345-347. [4] 刘会永,万象新,符孔,等.CT引导下经皮微波消融术与腹腔镜手术治疗原发性肝癌的疗效比较[J].介入放射学杂志,2019,28(10):991-995. [5] FINN R S,IKEDA M,ZHU A X,et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J].J Clin Oncol,2020,38(26):2960-2970. [6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90. [7] 金一帮,陈璐,童晓春,等.腹腔镜超声引导微波消融治疗原发性肝癌的疗效分析[J].腹腔镜外科杂志,2021,26(2):86-88. [8] WANG Y H,CHEN C B,TASSANEEYAKUL W,et al.The medication risk of stevens-johnson syndrome and toxic epidermal necrolysis in asians:the major drug causality and comparison with the US FDA label[J].Clin Pharmacol Ther,2019,105(1):112-120. [9] CHO I J,KIM J K,KIM E O,et al.Hemistepsin a induces apoptosis of hepatocellular carcinoma cells by downregulating STAT3[J].Int J Mol Sci,2021,22(9):4743. [10] 余守江,王国兴,马兰芳.TACE联合微波消融对原发性肝癌患者肿瘤组织灌注、免疫功能及预后的影响[J].肝脏,2020,25(3):294-296. [11] LOEUILLARD E,YANG J,BUCKARMA E,et al.Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma[J].J Clin Invest,2020,130(10):5380-5396. [12] 周晓思,秦蓉,赵红川,等.PD-1/PD-L1在原发性肝癌中的表达及临床意义[J].肝胆外科杂志,2019,27(1):66-69. [13] 胡泽明,陈彪,钟佳宁,等.原发性肝癌治疗方法的应用进展[J].山东医药,2019,59(9):106-110.
2023, Vol. 40 
